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We have employed unique properties of carbon-based as well as metallic nanomaterials to develop 
diagnostic / therapeutic devices targeted against thrombotic disorders. We have designed a novel 
graphene-based biosensor that can detect individuals with high coronary risk. Further, we describe an 
innovative strategy to ablate pathological thrombus in situ employing near-infrared laser-irradiated 
gold nanorods (photothermal therapy).
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ABSTRACT
Introduction
 Global status report of World Health 
Organization has categorized cardiovascular 
diseases, comprising of coronary artery disease, 
stroke, atherosclerosis and heart failure, as 
leading causes of death resulting in millions of 
casualties worldwide, followed by deaths due to 
diabetes.  According to the WHO projection, the 
spectrum of cardiovascular diseases will be the 
largest cause of disability and death in India by 
2020, thus replacing infectious diseases from 
that position.  Although cardiovascular diseases 
affect people with advanced age, risk factors 
may appear relatively early. One such risk factor 
is circulating Platelet-derived Micro Particles 
(PMPs) in blood of patients suffering from 
myocardial infarction or peripheral arterial 
diseases (1).  Elevated plasma levels of PMPs 
have been associated with enhanced risk of 
coronary heart disease in healthy individuals (2).
 Platelet activation is central to the 
pathogenesis of arterial thrombosis.  PMPs are 
membrane vesicles of less than 1 μm diameter 
released from stimulated platelets (3).  They 
play signiﬁcant role in haemostatic response and 
their presence in circulation represents serious 
procoagulantrisk.  Detection of PMPs at early 
stage of disease would aid in diagnosis, 
prevention and management of the pathology. 
Flow cytometry is the available technique for 
PMP detection but is associated with major 
drawbacks that include underestimation of PMP 
count, lack of universal standardization, time 
consuming experiments, high cost of the 
equipment and need for skilled operator. In 
contrast electrochemical biosensing stands far 
superior chance as an efﬁcient and affordable 
tool for PMP detection.
 'Biosensing' is an emerging concept based 
on amperometry, potentiometry and impedance 
analysis, which detects transduction of 
biological events to electrochemical signals with 
high sensitivity (4).  Nanoscale particles of gold, 
iron and silicon, as well as graphene and carbon 
n a n o t u b e s  h a v e  b e e n  e m p l o y e d  a s 
immobilization matrices during fabrication of 
electrodes.  Material immobilized on exposed 
surface of electrodes determines its speciﬁcity, 
which include enzymes, antibodies, proteins, 
aptamers or nucleotides depending upon the 
nature of the target. Although there has been 
attempt to detect microparticles using 
electrochemistry, the method does not 
differentiate between their cells of origin and 
types (5) and thus has limited medical 
application.  Here we describe a simple, quick, 
sensitive and cost-effective method to detect 
PMPs circulating in blood of individuals with 
potential for point-of-care diagnostic at 
peripheral health care system.  The novelty of 
this product lies in its ease of fabrication and 
detection method, as no electrochemical sensor 
has yet been reported which could facilitate 
quick screening and diagnosis of individuals at 
'high-risk' for developing cardiovascular 
diseases, eliminating requirement of high end 
lab facilities and experienced technicians as 
needed in current PMP detection procedures.
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Fig. 1. Schematic design of nano-biosensor for detection of PMPs depicting stepwise 
immobilization of GO and PAC1 antibody on electrode surface. Subsequent incubation of 
coated electrode with sample resulted in binding of platelet-derived microparticles, bearing 
active conformation of integrins α β , to the sensor surface, which can be detected 
IIb 3
by impedance analysis.
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 We have designed a graphene oxide-based 
electrochemical biosensor for detection of 
PMPs, a major risk factor for arterial pro-
thrombotic pathologies like acute myocardial 
infarction and ischemic stroke.  Electrodes were 
fabricated with immobilized layers of graphene 
oxide and a speciﬁc antibody targeted against 
active conformation of integrin α β  on PMP 
IIb 3
surface.  Results showed progressive rise in 
impedance in Nyquist plots with increasing 
number of PMPs in analyte. The sensor was 
highly speciﬁc for PMPs and did not identify 
microparticles originating from other cells. 
Blood obtained from patients diagnosed with 
acute myocardial  infarct ion exhibi ted 
signiﬁcantly higher values of impedance, 
consistent with larger number of circulating 
PMPs in these patients, as compared to samples 
from healthy individuals, thus validating 
biosensor as a speciﬁc, sensitive, label-free and 
cost-effective tool for rapid point-of-care 
detection of PMPs at bedside.  Our biosensor is 
most ideal for mass population screening 
programs at periphery-level healthcare units 
with limited resources.  It is aimed at early 
detection of individuals having higher imminent 
cardiovascular risk, as well as for routine 
analysis, which in turn would contribute to better 
management and survival of screened 'high-risk' 
subjects (6, 7). 
 Despite major scientiﬁc advances, non-
communicable diseases like acute myocardial 
infarction, cerebral ischemic stroke, and deep 
vein thrombosis, underpinned with vascular 
blockage mediated by thrombus, remain major 
causes of death, and morbidity across the globe, 
incidence of which far exceeds that of cancer. 
Medication with ﬁbrinolytic agents (tissue 
plasminogen activator, or tPA, streptokinase, 
and urokinase) are the widely used clinical 
practice that involves activation of plasminogen 
leading to  proteolyt ic  degradat ion of 
polymerized ﬁbrin clot.  However, ﬁbrinolytic 
therapy is frequently associated with serious 
life-threatening complications like severe 
haemorrhage, embolism, haemorrhagic stroke, 
and reperfusion arrhythmias, and requires 
consis tent  physician supervis ion,  and 
monitoring. Parenteral, or oral therapy would 
lead to generalized effect as it is not directed at 
localized clot, which, therefore, is another major 
limitation of this therapy.  In this study, we have 
exploited biocompatibility, and photothermal 
attributes of NIR-active materials like gold 
nanorods (8) to dissolve ﬁbrin clots at site of 
lesion, and restore lumen patency.  The so-called 
photothermal therapy has been widely suggested 
as an anti-cancer measure to ablate solid 
tumours.  This is the ﬁrst report on application of 
photothermal therapy as an anti-thrombotic 
measure.  The serine protease thrombin 
proteolytically degrades ﬁbrinogen, the soluble 
blood protein component, to ﬁbrin.  Fibrin 
monomers are held together by non-covalent 
bonds constituting the nascent insoluble 
thrombus, which are further cross-linked by 
transglutaminase action of clotting factor XIII. 
Subjecting thrombus to photothermal heating 
would lyse non-covalent interactions, resulting 
in loosening, and downsizing of clot. Force of 
arterial, or venous ﬂuid shear would disperse the 
remnants of loosened clot leading to drop in 
local concentration of polymerized ﬁbrin, and 
relief from occlusion.  Clot rareﬁcation would 
also facilitate permeation of thrombolytics 
inside the thrombus mass. 
 Fibrinolytic therapy for arterial or venous 
thrombotic disorders warrants systemic 
admin i s t r a t ion  o f  th romboly t i c s  l ike 
streptokinase, which is associated with serious 
bleeding complications. In this study, we have 
provided proof-of-concept of photothermal 
ablation of thrombus Thrombi were generated in 
vitro either from puriﬁed ﬁbrinogen or from 
plasma, or in vivo in murine blood vessels.  Gold 
nanorods were added on ﬁbrin-rich clots in vitro 
or targeted towards thrombi in situ in mice, 
followed by irradiation with a 808 nm near-
infrared laser source at power density of 1·05 
2
W/cm .  Local rise in temperature (up to 
55–65°C) was detected with an infrared thermal 
camera that leads to nearly 15% lysis of clot. 
This is the ﬁrst report on application of 
photothermal therapy as an anti-thrombotic 
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measure.  Remarkably, addition of streptokinase 
has a multimodal additive effect in accelerating 
the photothermal lysis of thrombi (up to 40%) 
even at a dose signiﬁcantly lower (by 30 to 50 
times) than therapeutic concentration, thus 
minimizing life-threatening side effects and 
adverse complications.  This combinatorial 
approach has great potential in bringing about 
lysis of pathological clots that can effectively 
overcome the drawbacks of existing therapies 
(9, 10).  Thus, the synergism between 
photothermal therapy and chemotherapy with 
reduced bleeding risk opens possibility of a 
smart and safe multimodal thrombolytic 
regimen for future.
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Fig. 2: Targeted photothermal therapy, when synergized with chemotherapy/thrombolytics 
at sub-therapeutic doses, exhibits great potential for the lysis of pathological clots 
with effective minimization of the life-threatening side effects and 
off-target adverse complications associated with existing therapy. 
This introduces the possibility of smart and safe multi modal 
thrombolytic regimen in the future.
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